Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

International Journal of Cancer. Journal International Du Cancer
Marianna C PolitouEvangelos Terpos

Abstract

Dickkopf-1 (DKK-1) protein, a soluble inhibitor of Wnt signalling, has been implicated in the pathogenesis of myeloma bone disease through the suppression of osteoblast differentiation. In this study, serum concentrations of DKK-1 were measured in 50 myeloma patients (32 at diagnosis and 18 before and after autologous stem cell transplantation (ASCT), 18 patients with monoclonal gammopathy of undetermined significance (MGUS), and 22 healthy controls. Serum DKK-1 levels were increased in MM at diagnosis compared with MGUS (mean +/- SD: 67 +/- 54 ng/mL vs. 38 +/- 13 ng/mL; p = 0.006) and controls (31 +/- 11 ng/mL; p = 0.02), while there was no difference between MGUS patients and controls. Although patients with stage 2 and 3 myeloma had higher DKK-1 values than stage 1 patients (79 +/- 63 vs. 40 +/- 13; p = 0.005), no significant correlation between serum DKK-1 and myeloma bone disease was observed. Myeloma patients before ASCT also had increased levels of DKK-1 (63 +/- 77 ng/mL; p = 0.03) compared with controls, supporting the notion that DKK-1 may be responsible for the suppressed osteoblast activity even in patients with low tumor burden. After ASCT, there was a sustained decrease in DKK-1 levels over time, while bone formati...Continue Reading

References

Nov 13, 2001·Developmental Cell·M MukhopadhyayH Westphal
Jun 26, 2003·British Journal of Haematology·Franco SilvestrisFranco Dammacco
Dec 26, 2003·The New England Journal of Medicine·Erming TianJohn D Shaughnessy
Feb 3, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·L Joseph MeltonRobert A Kyle
Apr 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip R GreippJan Westin

❮ Previous
Next ❯

Citations

Feb 4, 2010·Journal of Bone and Mineral Metabolism·G David Roodman
Sep 4, 2012·Current Hematologic Malignancy Reports·Evangelos TerposMeletios A Dimopoulos
Aug 13, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Ping Wu, Gareth J Morgan
Jan 15, 2014·BoneKEy Reports·Evangelos Terpos, Dimitrios Christoulas
Nov 29, 2008·Leukemia·G D Roodman
Aug 15, 2012·Nature Reviews. Rheumatology·Christos E LampropoulosDavid P D'Cruz
May 15, 2007·Blood·Evangelos TerposMeletios-Athanassios Dimopoulos
Oct 30, 2010·Journal of Experimental & Clinical Cancer Research : CR·Youxin ZhouXiuyun Wang
Sep 21, 2013·Calcified Tissue International·Natasa KovacicMichelle M McDonald
Nov 3, 2011·Bone Marrow Research·C F HealyP O'Sullivan
Sep 6, 2014·British Medical Bulletin·Rebecca E WalkerAndrew D Chantry
Jun 18, 2009·Expert Opinion on Therapeutic Targets·Maria GavriatopoulouEvangelos Terpos
Oct 15, 2008·Expert Opinion on Therapeutic Targets·G David Roodman
Jul 6, 2012·Expert Opinion on Therapeutic Targets·Maria GkotzamanidouEvangelos Terpos
Aug 1, 2009·Expert Review of Hematology·Dimitrios ChristoulasMeletios A Dimopoulos
Nov 13, 2014·Expert Opinion on Biological Therapy·Yvonne Mary PapamerkouriouJohn Kyrkos
Oct 21, 2009·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Xiao YaoJianren Gu
Jul 17, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Hye Seung LeeKyoung Un Park
Jun 26, 2012·Seminars in Hematology·Ya-Wei QiangJoshua Epstein
Jul 10, 2010·Bone·Jessica A FowlerPeter I Croucher
Jul 6, 2010·Bone·G David Roodman
Apr 25, 2009·Clinical Biochemistry·Michael J MarshallMichael W J Davie
Oct 10, 2006·Clinical Lymphoma & Myeloma·Maurizio ZangariGuido Tricot
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Klaus PodarKenneth C Anderson
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Flavia R Esteve, G David Roodman
Nov 13, 2007·Hematology/oncology Clinics of North America·Suzanne LentzschG David Roodman
Sep 25, 2007·Experimental Hematology·Mihaela ZleiMonika Engelhardt
Aug 8, 2009·Cancer Science·Akira MatsuiNobuyuki Enomoto
Oct 2, 2007·Arthritis and Rheumatism·Nancy E LaneUNKNOWN Study of Osteoporotic Fractures Research Group
Mar 12, 2008·European Journal of Haematology·Martin KaiserUlrike Heider
Jul 28, 2012·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Mohammed-Salleh M ArdawiShaker A Mousa
Sep 29, 2011·International Journal of Cancer. Journal International Du Cancer·Mitchell E MenezesRajeev S Samant

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.